Esophageal cancer · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
FOLFOX4 and RT Variant #01 | — | R 4 783 | 35d | — | — | — | — | — |
Capecitabine and Cisplatin (CX) and RT Variant #03 | — | R 3 674 | 42d | — | ~34.5 mo | — | — | 1 |
Cisplatin and Fluorouracil (CF) and RT Variant #13 | — | R 1 850 | 28d | ~16.0 mo | ~44.1 mo | ~18 | ~R 33 301 PFS proxy · indirect | 4 |
Cisplatin and Paclitaxel (TP) and RT N/A - secondary systemic drug | — | R 350 | 28d | — | — | — | — | 1 |
Cisplatin and Docetaxel (DC) and RT N/A - secondary systemic drug | — | R 176 | — | — | — | — | — | — |
Radiation therapy N/A - radiation Partial | — | — | 49d | — | ~9.2 mo | — | — | 1 |
S-1 and RT Variant #01 Partial | — | — | 42d | — | — | — | — | 1 |
7 of 7 regimens shown